Japanese researchers have developed a new test that could quickly determine whether you have Covid-19 with a glowing chemical.
Using
a molecule found in crustaceans, the team from Japan Science and Technology
Agency (JST) developed a rapid approach that detects SARS-CoV-2 protein
comparably to one used in vaccine research.
From
fireflies to lantern fish, many animals possess the chemical tools to produce
light. Typically, this reaction requires the substrate luciferin and the enzyme
luciferase.
However,
a class of less discriminating luciferins, known as imidazopyrazinone-type
(IPT) compounds, can glow when encountering other proteins, including ones that
aren't considered enzymes, the researchers reported in the journal ACS Central
Science.
Previous
research suggests that IPT luciferins could serve as the basis for a new type
of medical test that uses luminescence to announce the presence of a target
protein in a specimen.
The
team led by Ryo Nishihara and Ryoji Kurita from JST suspected that an IPT
luciferin could react with the SARS-CoV-2 spike protein, which allows the virus
particles to invade cells and cause Covid -- and open the door to develop a
glowing test.
The
team first investigated 36 different IPT luciferins' abilities to react with a
single unit of spike protein. Only one molecule, which came from tiny
crustaceans from the genus Cypridina, emitted light.
The
researchers then tested the luciferin's activity with the spike protein in its
natural state, as three units folded together.
They
found that, over the course of 10 minutes, an adequate amount of light could be
detected.
A
commercially available luminescence reading device was required; the light
could not be seen by the naked eye.
Additional
experiments indicated that the IPT luciferin was selective because it did not
glow when exposed to six proteins that occur in saliva.
They
define this specific luminescence reaction by non-luciferase biomolecules as
“biomolecule-catalysing chemiluminescence (BCL)”.
Finally,
the team found that the luciferin could detect the amount of the spike protein
in saliva with the same accuracy as a technique currently used in vaccine
development.
However,
the luciferin system delivered results in one minute — significantly faster
than the current rapid point-of-care tests.
This
BCL-based approach could serve as the basis for a simple “mix and read” test in
which the IPT luciferin is added to untreated saliva from someone suspected of
having Covid-19, according to the researchers.
They note that a similar
approach could be adapted to detect other viruses that possess spike-like
proteins, such as influenza, MERS-CoV and other coronaviruses.
No comments:
Post a Comment